ADVERTISEMENT

Clinical Summary

Venous thromboembolism: benefits of extended rivaroxaban thromboprophylaxis

Jenny Blair, MD   |   17 October 2022

Takeaway

  • For selected patients at risk for venous thromboembolism (VTE) after medical hospitalization, extended rivaroxaban thromboprophylaxis may be beneficial.

Why this matters

  • Rivaroxaban, a direct anticoagulant, is FDA-approved for posthospitalization thromboprophylaxis.
  • However, in MAGELLAN study, patients with several risk factors (e.g., active cancer or recent bleeding) had higher bleeding risk.
  • This...

          

November Challenge

Ends in 10h
left
right

Topic Challenges

left
right